Conditions: Neoplasms, Breast
Keywords: breast cancer brain metastases ErbB2 positive HER2 positive neoplasms cancer lapatinib LAP016A2202 LAP016A CLAP016A2202 GW572016
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 242
Healthy volunteers: no

Brief summary:
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.

Detailed description:

Arms:
arm 1: 750 mg lapatinib administered orally twice daily

Interventions: intervention 1: lapatinib
Intervention descriptions: intervention 1: tyrosine kinase inhibitor

Protocol document: